NCT04860154 is a NA clinical trial of Hematoporphyrin in Cholangiocarcinoma Non-resectable, sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province.

Who is sponsoring NCT04860154?

NCT04860154 is sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province.

What drugs are being tested in NCT04860154?

Interventions in NCT04860154: Hematoporphyrin.

What condition does NCT04860154 study?

NCT04860154 studies Cholangiocarcinoma Non-resectable.

Is NCT04860154 still recruiting?

NCT04860154 is currently completed. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT04860154

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Photodynamic Therapy for Cholangiocarcinoma

Completed NA Last updated 20 November 2024

What this trial tests

NA trial testing Hematoporphyrin in Cholangiocarcinoma Non-resectable in 86 participants. Completed in 19 November 2024.

Timeline

17 April 2021

Primary endpoint
19 November 2024

19 November 2024

Quick facts

Lead sponsor	Hepatopancreatobiliary Surgery Institute of Gansu Province
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	86
Start date	17 April 2021
Primary completion	19 November 2024
Estimated completion	19 November 2024
Sites	11 locations across China

Drugs / interventions tested

Hematoporphyrin (Hematoporphyrin) — full drug profile →

Conditions studied

Cholangiocarcinoma Non-resectable — all drugs for Cholangiocarcinoma Non-resectable →

Sponsor

Hepatopancreatobiliary Surgery Institute of Gansu Province

Who can join

Adults 18 to 80, any sex, with Cholangiocarcinoma Non-resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of the bile duct patency with photodynamic therapy (PDT) and regular Endoscopic Retrograde Cholangiopancreatography(ERCP) stents in unresectable cholangiocarcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.
Penetra M, Arnaut LG, Gomes-da-Silva LC. · · 2023 · cited 36× · PMID 37346450 · DOI 10.1080/2162402x.2023.2226535

Verify or expand the search:

Other recruiting trials for Cholangiocarcinoma Non-resectable

Currently open trials in the same condition.

NCT06850753 — En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve th · NA · recruiting
NCT06192797 — Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma · Phase 2 · recruiting
NCT05655949 — Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio · Phase 2 · recruiting
NCT05978609 — Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer · Phase 2 · recruiting
NCT06487663 — TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors · NA · recruiting

Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials

Trials by the same sponsor.

NCT03104569 — Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma · NA · not yet recruiting
NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
NCT06697405 — Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04860154 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04860154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing